Close menu




Comments

Photo credits: pixabay.com

Commented by Armin Schulz on August 18th, 2025 | 07:10 CEST

Hydrogen renaissance – Plug Power, Pure Hydrogen, and Nel ASA want a slice of the USD 680 billion pie

  • Hydrogen
  • GreenTech
  • greenhydrogen
  • renewableenergies

The global hydrogen economy is on the verge of a breakthrough. This is being driven by multi-billion-dollar decarbonization targets, the quest for independence from fossil fuels, and falling costs for renewable energy. Demand could increase fivefold by 2050. By 2035, 60% of energy demand is expected to come from clean production, supported by over 1,500 large-scale projects worldwide. Despite gaps between planning and implementation, investments of up to USD 680 billion in the coming years and groundbreaking industry contracts signal an irreversible transformation. Amid this momentum, three key players are strategically positioning themselves: Plug Power, Pure Hydrogen, and Nel ASA.

Read

Commented by André Will-Laudien on August 18th, 2025 | 07:05 CEST

Hydrogen versus nuclear power – 300% with Plug Power and dynaCERT, caution advised with Oklo and NuScale

  • Hydrogen
  • GreenTech
  • greenhydrogen
  • nuclear

Fuel cells have long been seen as a beacon of hope in propulsion technology, though they have only gained limited traction in the automotive sector. While batteries dominate the mass market, fuel cells score points primarily in heavy-duty and long-distance transport due to their range and short refueling times, as well as in stationary systems. Plug Power is working on infrastructure projects, while dynaCERT is making existing drives more efficient with hydrogen systems, thus serving as a bridge to the next era. At the same time, small modular reactors (SMRs) from suppliers like Oklo and NuScale are gaining in importance as they promise a stable, low-carbon energy supply for industry and hydrogen production. This opens up opportunities for investors in two future markets: sustainable mobility and scalable energy solutions – both enjoying political tailwinds and high growth potential. How should investors proceed with their portfolios?

Read

Commented by Stefan Feulner on August 18th, 2025 | 07:00 CEST

Uranium Energy, Almonty Industries, Bayer – Rebound after correction

  • Mining
  • Tungsten
  • Uranium
  • Pharma
  • Defense

The peace summit between the US and Russia is already history and yielded few results in terms of ending the war in Ukraine. While the indices remained stable last week, short, sharp setbacks in selected stocks could offer interesting entry opportunities at the start of the week. Uncertainty also continues to prevail with regard to tariffs. Although the tariffs for India and China have been postponed, a final agreement is still a long way off.

Read

Commented by Fabian Lorenz on August 15th, 2025 | 07:05 CEST

Up to 100% in a month, and now? D-Wave, Palantir, and Hotstock PanGenomic Health

  • healthtech
  • computing
  • Software

PanGenomic Health's stock has roughly doubled in the past four weeks. The healthcare hot stock has even outpaced Palantir and D-Wave. Of course, the base is significantly lower. PanGenomic continues to be valued at less than CAD 30 million, which means that the rally could continue with the launch of the app platform in the second half of the year. D-Wave has impressively demonstrated that a stock can increase tenfold within a few months. There is positive news from Asia for the quantum high-flyer. The quarterly figures were mixed, but analysts focused on the stronger-than-expected revenue growth. Palantir is also valued more than generously. Nevertheless, there are price targets above the current level. But caution is advised, as short sellers are also positioning themselves.

Read

Commented by Armin Schulz on August 15th, 2025 | 07:00 CEST

War and raw material shortages = Your profit: How Rheinmetall, Almonty Industries, and RENK are now cashing in

  • Mining
  • Tungsten
  • Defense
  • Investments

The global security architecture is collapsing, and with it, the rules of the game in the defense industry are changing. While superpowers like the US are pumping billions into strategic raw materials to break critical import dependencies, resource security is becoming the new currency of military strength. Tungsten, rare earths, and high-performance metals are now decisive factors in technological sovereignty. Those who take advantage of this shift stand to benefit from unprecedented government initiatives. Three companies are positioning themselves decisively in this area: Rheinmetall, Almonty Industries, and RENK.

Read

Commented by Fabian Lorenz on August 14th, 2025 | 07:15 CEST

BOMBSHELL! RENK, Bayer, Desert Gold! Who has the potential to multiply?

  • Mining
  • Gold
  • Defense
  • Pharma

Bombshell at RENK! Order intake is exploding! Revenue and earnings are also already up significantly. After Rheinmetall and Hensoldt posted rather disappointing figures, the defense boom appears to be reaching the tank transmission specialist. The stock is reacting strongly. Meanwhile, the share price of gold explorer Desert Gold has not yet responded to the recent Preliminary Economic Assessment (PEA). This is surprising, as the returns are high - even with the conservative gold price assumptions. In an interview with analysts, the CEO once again explains the opportunities. GBC Research sees potential for multiplication here. At Bayer, investors have recently been focusing more on litigation risks in the US than on upside potential. However, the latest news from the pharmaceutical division is driving the Leverkusen-based company's shares up again. Is the weak phase finally over?

Read

Commented by Nico Popp on August 14th, 2025 | 07:10 CEST

High flyers are emerging here: NetraMark, Bechtle, Adesso

  • Biotechnology
  • AI
  • IT

Sometimes you need an outside opinion. Consulting firms have been cashing in on this for decades. Especially when it comes to new technologies, fresh external input makes sense. McKinsey consultants estimate that the rapid deployment of modern technology alone can lead to productivity gains of 3% - year after year. No wonder, then, that external service providers are in demand in an increasing number of industries and are creating added value. We explain the opportunities these companies can offer investors.

Read

Commented by Armin Schulz on August 14th, 2025 | 07:05 CEST

How Volkswagen, Power Metallic Mines, and Nordex aim to conquer the trillion-dollar energy transition market

  • Mining
  • Nickel
  • Copper
  • RareEarths
  • renewableenergies
  • Energy
  • Electromobility

Electrification is driving an unprecedented demand for raw materials. Lithium, cobalt, and rare earths are the new oil - essential for electric vehicles, wind turbines, and our climate-neutral future. But global dependencies and trade conflicts threaten to disrupt supply chains. Those who secure strategic supplies will dominate the transition. Today, we look at three companies that are benefiting from the energy transition – Volkswagen, Power Metallic Mines and Nordex – and analyze their current situation.

Read

Commented by Stefan Feulner on August 14th, 2025 | 07:00 CEST

Plug Power, Pure Hydrogen, RENK – The order books are filling up

  • Hydrogen
  • greenhydrogen
  • cleantech
  • Defense

The stock markets are celebrating as if there were no tomorrow. But caution is advised! The ambitious valuations of many companies are likely to result in a sharp correction in the near future. Stock picking is currently the order of the day, because we saw how quickly high prices can evaporate into thin air at the beginning of April when Donald Trump unveiled his tariff measures. But there are still some undiscovered gems out there. In the hydrogen sector in particular, a previously unknown company has made a name for itself with two future-oriented orders.

Read

Commented by André Will-Laudien on August 13th, 2025 | 07:15 CEST

Attention, Takeovers: Things are heating up! Bayer, Eli Lilly, Vidac Pharma, and Formycon in focus

  • Biotechnology
  • Biotech
  • Pharma

Volatility is king! Great for speculators, often difficult for long-term investors. Biotech stocks are extremely sensitive to study and approval news, especially in cancer research. Vidac Pharma is developing drugs that are designed to target tumor cells and cause them to die – risky, but with great potential. Despite its restructuring, Bayer is strengthening its oncology pipeline, especially in niche indications. Eli Lilly is benefiting from the boom in modern immunotherapies and, thanks to its strong financial position, can support long development phases. Formycon is considering entering the oncology market to broaden its base. The sector offers opportunities and surprising takeovers, but requires a high tolerance for risk.

Read